NeuBase Therapeutics Company Overview
About NeuBase Therapeutics
NeuBase Therapeutics (NASDAQ:NBSE) focuses on advancing the field of genetics by developing therapeutic tools to tackle genetic diseases at their core. This innovative biotech firm is pioneering a unique platform aimed at addressing genetic mutations with precision and scalability, targeting a wide array of genetic disorders. With a commitment to leveraging cutting-edge technology to bring transformative treatments to patients who currently have limited options, NeuBase is at the forefront of delivering on the promise of personalized medicine. Their projects span from early-stage developments in drug design and delivery to collaborative efforts aimed at tackling some of the most challenging genetic conditions. Through its ambitious objectives, NeuBase aims to significantly improve the lives of individuals living with genetic diseases, showcasing a clear dedication to scientific excellence and patient-centric healthcare solutions.
Snapshot
Operations
Produtos e/ou serviços de NeuBase Therapeutics
- Development of a gene silencing technology aimed at treating Huntington's disease.
- Creation of a platform for targeted, programmable gene editing to combat genetic disorders.
- Research into therapies for myotonic dystrophy, focusing on RNA-targeted treatments.
- Advancement of a drug candidate for the treatment of ALS, leveraging antisense oligonucleotides.
- Innovation in the delivery mechanisms of genetic medicines, enhancing cell-specific targeting.
- Exploration of solutions for rare genetic diseases through the use of precision genetic medicine technology.
equipe executiva do NeuBase Therapeutics
- Mr. Todd P. BranningInterim CEO, CFO & Secretary
- Dr. Dietrich A. Stephan Ph.D.Founder, President & Director